

 PALM INTRANET

Day : Wednesday

Date: 11/7/2007

Time: 13:12:56

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Welcome to DialogClassic Web(tm)

Dialog level 05.20.01D

Last logoff: 02nov07 15:17:49

Logon file: 07nov07 17:11:13

*** ANNOUNCEMENTS ***

NEW FILES RELEASED

***BIOSIS Previews Archive (File 552)

***BIOSIS Previews 1969-2007 (File 525)

***Trademarkscan - South Korea (File 655)

RESUMED UPDATING

***File 141, Reader's Guide Abstracts

RELOADS COMPLETED

***File 5, BIOSIS Previews - archival data added

***Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online

NEWS

Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).

>>>For the latest news about Dialog products, services, content<<< >>>and events,
>>><http://www.dialog.com/whatsnew/>. You can find news about<<<
>>>a specific database by entering HELP NEWS <file number>.<<<
>>>PROFILE is in a suspended state.
>>>Contact Dialog Customer Services to re-activate it.

* * *

File 1:ERIC 1965-2007/Sep

(c) format only 2007 Dialog

Set Items Description

--- -----

Cost is in DialUnits

?

B 155, 159, 5, 73

07nov07 17:11:29 User259876 Session D1049.1

\$0.98 0.279 DialUnits File1

\$0.98 Estimated cost File1

\$0.06 INTERNET

\$1.04 Estimated cost this search

\$1.04 Estimated total session cost 0.279 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1950-2007/Nov 05

(c) format only 2007 Dialog

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog

*File 159: Cancerlit is no longer updating.

Please see HELP NEWS159.

File 5:BIOSIS Previews(R) 1926-2007/Nov W1

(c) 2007 The Thomson Corporation

File 73:EMBASE 1974-2007/Nov 05

(c) 2007 Elsevier B.V.

*File 73: Embase will be reloaded soon. Accession numbers

will change.

| Set | Items | Description |
|-----|---|---|
| --- | ----- | ----- |
| ? | | |
| S | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED O Processing | |
| | 11262 | HSC |
| | 536710 | STEM |
| | 6409113 | CELLS |
| | 178160 | STEM(W) CELLS |
| | 1509242 | BONE |
| | 584546 | MARROW |
| | 553092 | BONE(W) MARROW |
| | 3113275 | DNA |
| | 362034 | VECTOR |
| | 192415 | TRANSFECTED |
| | 206579 | GENETICALLY |
| | 651532 | MODIFIED |
| | 37709 | GENETICALLY(W) MODIFIED |
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| ? | | |
| S | (RIBOZYME) (S) (TAT AND HIV) | |
| | 12135 | RIBOZYME |
| | 25199 | TAT |
| | 459839 | HIV |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| ? | | |
| S | S1 AND S2 | |
| | 41571 | S1 |
| | 154 | S2 |
| S3 | 10 | S1 AND S2 |
| ? | | |
| RD | | |
| | S4 | 6 RD (unique items) |
| ? | | |
| T | S4/3,K/ALL | |

4/3,K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

14073214 PMID: 12498773

RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.

Bai Jirong; Banda Nirmal; Lee Nan Sook; Rossi John; Akkina Ramesh

Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, USA.

Molecular therapy - the journal of the American Society of Gene Therapy (United States) Dec 2002, 6 (6) p770-82, ISSN 1525-0016--Print

Journal Code: 100890581

Contract/Grant No.: AI 42551; AI; NIAID; AI 42552; AI; NIAID; AI 50492; AI; NIAID

Publishing Model Print

Document type: Journal Article; Research Support, U.S. Gov't, P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Effective suppression of HIV -1 replication requires inhibition of critical viral target molecules. Tat and Rev are indispensable regulatory factors for HIV -1 replication, whereas Env mediates virus entry by direct interaction with surface receptor CD4 and coreceptor CCR5 or CXCR4. Anti-HIV -1 tat -rev and env ribozymes and Rev aptamers were previously demonstrated to provide relatively long-term protection against HIV -1 infection in vitro. However, further improvements in these constructs for clinical application in a...

... end, we introduced these constructs into CD34(+) hematopoietic progenitor cells by retrovirus-mediated gene transduction. Ribozyme - and aptamer-transduced CD34(+) cells differentiated normally into multiple lineages of erythroid and myeloid progenies...

... a colony-forming unit assay. Macrophages that differentiated from the transduced CD34(+) cells expressed anti- tat -rev and -env ribozymes and Rev aptamers and displayed their normal characteristic surface markers CD14 ...

... and CCR5. Using the SCID-hu mouse in vivo human thymopoiesis model, we demonstrated that ribozyme - and aptamer-transduced CD34(+) cells retained their normal capacity to reconstitute human fetal thymus and liver tissue (thy/liv) grafts. Reconstitution by ribozyme - and aptamer-transduced CD34(+) cells reached levels of up to 87% based on HLA surface marker staining. Differentiated thymocytes derived from reconstituted grafts expressed anti- tat -rev and -env ribozymes and Rev aptamers and showed significant resistance to HIV -1 infection upon challenge. Analysis of reconstituted thymocytes by hybridization revealed an average of 0...

...thymocytes demonstrated that the human thy/liv grafts were reconstituted by a few primitive hematopoietic stem cells. These results highlight the utility of RNA-based anti- HIV -1 gene therapeutic approaches and their preclinical testing in a surrogate animal model harboring human...

4/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

11283490 PMID: 9116267

Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.

Bauer G; Valdez P; Kearns K; Bahner I; Wen S F; Zaia J A; Kohn D B

Department of Pediatrics, University of Southern California School of Medicine, Los Angeles, USA.

Blood (UNITED STATES) Apr 1 1997, 89 (7) p2259-67, ISSN 0006-4971--
Print Journal Code: 7603509

Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Transfer of "anti- HIV -1 genes" into hematopoietic stem cells of human immunodeficiency virus-1 (HIV -1)-infected individuals may be a potent therapeutic approach to render mature cells arising from transduced stem cells resistant to the destructive events associated with HIV -1 infection. To determine the feasibility of gene therapy for acquired immunodeficiency syndrome in individuals already infected with HIV -1, granulocyte colony-stimulating factor mobilized peripheral blood CD34+ cells were isolated from HIV -1-infected individuals and transduced with retroviral vectors containing three different anti- HIV -1-genes: the Rev binding domain of the Rev Responsive Element (RRE decoy) (L-RRE-neo), a double hammerhead ribozyme vector targeted to cleave the tat and rev transcripts (L-TR/ TAT -neo), and the trans-dominant mutant of rev (M10) (L-M10-SN). As a control, a vector mediating only neomycin resistance (LN) was used. After 3 days of transduction on allogeneic stroma...

...6 (IL-6), and IL-3, the cultures were G418-selected, and then challenged with HIV -1(JR-FL) and a primary HIV -1 isolate. Compared with the control cultures, the L-RRE-neo-, L-TR/ TAT -neo-, and L-M10-SN-transduced cultures displayed up to 1,000-fold inhibition of HIV -1 replication after challenge with HIV -1(JR-FL) and the primary HIV -1 isolate. Growth of the hematopoietic cells in long-term bone marrow culture was not perturbed by the presence of any of the anti- HIV -1 genes. This study shows that anti- HIV -1 genes can be introduced into CD34+ cells from individuals already infected with HIV -1, and strongly inhibit HIV -1 replication in primary monocytes derived from the CD34+ progenitors.

4/3,K/3 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

10215739 PMID: 7958986

Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.

Zhou C; Bahner I C; Larson G P; Zaia J A; Rossi J J; Kohn E B

Childrens Hospital Los Angeles, Department of Pediatrics, University of Southern California School of Medicine, Los Angeles 90027.

Gene (NETHERLANDS) Nov 4 1994, 149 (1) p33-9, ISSN 0378-1119--Print Journal Code: 7706761

Contract/Grant No.: AI 29329; AI; NIAID; AI-125959; AI; NIAID; NS-26991; NS; NINDS

Publishing Model Print

Document type: Journal Article; Research Support, U.S. Gov't, P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Gene therapy for AIDS requires the identification of genes which effectively inhibit HIV -1 replication coupled to an efficient vector system for gene delivery and expression. Hammerhead ribozymes...

... capable of catalytic cleavage of complementary RNA molecules. Ribozymes targeted against two portions of the HIV -1 genome were designed to cleave HIV RNA in the tat gene (TAT) or in a common exon for tat and rev (TR). The ribozymes were cloned into the LN (LTR-neomycin) retroviral vector plasmids...

... virions and used to transduce human T-lymphocytes. Expression of the vector transcripts containing the ribozyme sequences was readily detected by Northern blot analysis of the transduced T cells. The T-lymphocytes

expressing the anti- HIV -1 ribozymes showed resistance to HIV -1 replication. In contrast, cells expressing mutant ribozymes, containing substitutions of a key nucleotide in the catalytic domain which cripples the cleavage activity of the ribozymes, supported replication of HIV -1, demonstrating that the functional ribozymes were cleaving the target RNAs. These studies demonstrate that retrovirally transduced ribozymes included in long, multifunctional transcripts, can inhibit HIV replication in human T-lymphocytes. The ribozyme and expression strategies described here should be useful for the gene therapy of AIDS by conferring resistance to HIV -1 replication on cells derived from transduced hematopoietic stem cells .

4/3,K/4 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

0019597498 BIOSIS NO.: 200700257239

Autologous stem cell transplantation (ASCT) for AIDS-related lymphomas (ARL) and the potential role of HIV-resistant stem cells.

AUTHOR: Krishnan Amrita Y (Reprint); Zaia John A; Rossi John J; Molina Arturo; Li Mingjie; Lee Wendy; Akkina Ramesh; Tsai Nicole; Li Shirley; Yam Priscilla; Li Haitang; Yee Jiing-Kuan; Hsu David; Couture Larry; DiGiusto David; Forman Stephen J

AUTHOR ADDRESS: City Hope Canc Ctr, Beckman Res Inst, Duarte, CA USA**USA

JOURNAL: Blood 108 (11, Part 1): p149A NOV 16 2006 2006

CONFERENCE/MEETING: 48th Annual Meeting of the American-Society-of-Hematology Orlando, FL, USA December 09 -12, 2006; 20061209

SPONSOR: Amer Soc Hematol

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: of ARL relies on both effective anti-tumor chemotherapy and successful control of the underlying HIV infection. Management of HIV using HAART has been hampered by patient non-compliance with complex regimens, drug resistance and ongoing low level viral replication. Multiplexed RNA based anti- HIV gene transfer strategies to confer intrinsic cellular resistance may help circumvent these problems. Autologous stem...

...combining gene transfer strategy with high dose antilymphoma therapy could provide control of both the HIV infection and the ARL. Methods: Gene transfer - anti- HIV RNA elements, including short hairpin RNA (shRNA) targeted to HIV tat /rev a TAR-specific decoy sequence, and a ribozyme targeted to CCR5 were combined into a lentivirus vector (LV, rHIV7-shI-TAR-CCR5RZ). Using LV transduction methods, these anti- HIV RNAs were delivered into CD34+ hematopoietic progenitor cells (HPC). Results: Preclinical vector development - LV transduction allowed differentiation in liquid culture and in a SCID-hu model which produced macrophage and T cell progeny that were resistant to the HIV virus. Although HIV resistance can be induced in vitro with single anti- HIV shRNAs, no resistance was found in multiply passaged HIV in rHIV7-shI-TAR-CCR5RZ-transduced cells. In addition, cells were analyzed by microarray for...

...analysis localized to transcriptionally active sites, usually away from terminal portions of gene sequences. This vector is proposed for use in

ASCT for ARL. Update of ASCT in ARL: Between 1998...

...in one patient who ultimately died of MDS while in remission from his ARL. Median HIV viral load (VL) at ASCT was 6113 gc/ml with 22 having an undetectable VL...

...remission for ARL. The fluctuation in VL seen post ASCT reflects the natural history of HIV infection and limitations of current antiviral therapy. Ultimately the system of gene transfer outlined above...

...of cure for pts with high-risk ARL by offering both effective antilymphoma and anti- HIV therapy.

4/3,K/5 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

11908927 EMBASE No: 2003019169

RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model

Bail J.; Banda N.; Lee N.S.; Rossi J.; Akkina R.

R. Akkina, Dept. of Microbiol. Immunol./Pathol., Colorado State University, Fort Collins, CO 80523 United States

AUTHOR EMAIL: akkina@colostate.edu

Molecular Therapy (MOL. THER.) (United States) 01 DEC 2002, 6/6 (770-782)

CODEN: MTOHC ISSN: 1525-0016

DOCUMENT TYPE: Journal ; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 56

Effective suppression of HIV -1 replication requires inhibition of critical viral target molecules. Tat and Rev are indispensable regulatory factors for HIV -1 replication, whereas Env mediates virus entry by direct interaction with surface receptor CD4 and coreceptor CCR5 or CXCR4. Anti-HIV -1 tat -rev and env ribozymes and Rev aptamers were previously demonstrated to provide relatively long-term protection against HIV -1 infection in vitro. However, further improvements in these constructs for clinical application in a...

...end, we introduced these constructs into CD34SUP+ hematopoietic progenitor cells by retrovirus-mediated gene transduction. Ribozyme - and aptamer-transduced CD34SUP+ cells differentiated normally into multiple lineages of erythroid and myeloid progenies...

...a colony-forming unit assay. Macrophages that differentiated from the transduced CD34SUP+ cells expressed anti- tat -rev and -env ribozymes and Rev aptamers and displayed their normal characteristic surface markers CD14 ...

...and CCR5. Using the SCID-hu mouse in vivo human thymopoiesis model, we demonstrated that ribozyme - and aptamer-transduced CD34SUP+ cells retained their normal capacity to reconstitute human fetal thymus and liver tissue (thy/liv) grafts. Reconstitution by ribozyme - and aptamer-transduced CD34SUP+ cells reached levels of up to 87% based on HLA surface marker staining. Differentiated thymocytes derived from reconstituted grafts expressed anti- tat -rev and -env ribozymes and Rev aptamers and showed significant resistance to HIV -1 infection upon challenge. Analysis of reconstituted thymocytes by hybridization revealed an average of 0...

...thymocytes demonstrated that the human thy/liv grafts were reconstituted by a few primitive hematopoietic stem cells. These results highlight the utility of RNA-based anti- HIV -1 gene therapeutic approaches and their preclinical testing in a surrogate animal model harboring human...

4/3,K/6 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2007 Elsevier B.V. All rts. reserv.

06817311 EMBASE No: 1997099803

Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34sup + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes

Bauer G.; Valdez P.; Kearns K.; Bahner I.; Sui Fang Wen; Zaia J.A.; Kohn D.B.

Dr. D.B. Kohn, DRIBMT, Childrens Hospital Los Angeles, Mailstop 62, 4650 Sunset Blvd, Los Angeles CA 90027 United States

Blood (BLOOD) (United States) 1997, 89/7 (2259-2267)

CODEN: BLOOA ISSN: 0006-4971

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 22

Transfer of 'anti- HIV -1 genes' into hematopoietic stem cells of human immunodeficiency virus-1 (HIV -1)-infected individuals may be a potent therapeutic approach to render mature cells arising from transduced stem cells resistant to the destructive events associated with HIV -1 infection. To determine the feasibility of gene therapy for acquired immunodeficiency syndrome in individuals already infected with HIV -1, granulocyte colony- stimulating factor mobilized peripheral blood CD34sup + cells were isolated from HIV -1-infected individuals and transduced with retroviral vectors containing three different anti- HIV -1-genes: the Ray binding domain of the Rev Responsive Element (RRE decoy) (L-RRE-neo), a double hammerhead ribozyme vector targeted to cleave the tat and rev transcripts (L-TR/ TAT -neo), and the trans-dominant mutant of rev (M10) (L-M10-SN). As a control, a vector mediating only neomycin resistance (LN) was used. After 3 days of transduction on allogeneic stroma...

...6 (IL-6), and IL-3, the cultures were G418-selected, and then challenged with HIV -1(JR-FL) and a primary HIV -1 isolate. Compared with the control cultures, the L-RRE-neo-, L-TR/ TAT -neo-, and L-M10-SN-transduced cultures displayed up to 1,000-fold inhibition of HIV -1 replication after challenge with HIV -1(JR-FL) and the primary HIV -1 isolate. Growth of the hematopoietic cells in long-term bone marrow culture was not perturbed by the presence of any of the anti- HIV -1 genes. This study shows that anti- HIV -1 genes can be introduced into CD34sup + cells from individuals already infected with HIV -1, and strongly inhibit HIV -1 replication in primary monocytes derived from the CD34sup + progenitors.

?

| Set | Items | Description |
|-----|-------|---|
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| S3 | 10 | S1 AND S2 |
| S4 | 6 | RD (unique items) |

?

S (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING)

| | |
|---------|------------|
| 981524 | SEX |
| 348600 | STEROID |
| 1696882 | INHIBITION |
| 180554 | DISRUPTION |
| 26864 | BLOCKAGE |
| 25544 | DISRUPTING |

S5 760 (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING)

?

S S1 AND S5

| | |
|-------|----|
| 41571 | S1 |
| 760 | S5 |

S6 0 S1 AND S5

?

| Set | Items | Description |
|-----|-------|---|
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| S3 | 10 | S1 AND S2 |
| S4 | 6 | RD (unique items) |
| S5 | 760 | (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING) |
| S6 | 0 | S1 AND S5 |

?

S S1 AND (LEUPROLIDE)

| | |
|-------|------------|
| 41571 | S1 |
| 5753 | LEUPROLIDE |

S7 1 S1 AND (LEUPROLIDE)

?

T S7/3,K/ALL

7/3,K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

08321707 PMID: 2532849

Effect of GnRH agonists on the thymus in female rats.

Ataya K M; Sakr W; Blacker C M; Mutchnick M G; Latif Z A

Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI.

Acta endocrinologica (DENMARK) Dec 1989, 121 (6) p833-40, ISSN 0001-5598--Print Journal Code: 0370312

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... 10 and 18 days of GnRH agonist treatment. No consistent increases in splenic weight or bone marrow cell counts were observed. Thymosin alpha-1 but not thymosin beta-4 increased in GnRH...

...; effects--DE; Bone Marrow--pathology--PA; Buserelin--pharmacology--PD; Gonadotropin-Releasing Hormone--pharmacology--PD; Goserelin;

Leuprolide ; Organ Size--drug effects--DE; Rats; Rats, Inbred Strains;
Spleen--drug effects--DE; Spleen--pathology...

Chemical Name: Gonadotropin-Releasing Hormone; Leuprolide ; Buserelin;
Goserelin

?

| Set | Items | Description |
|-----|-------|---|
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| S3 | 10 | S1 AND S2 |
| S4 | 6 | RD (unique items) |
| S5 | 760 | (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING) |
| S6 | 0 | S1 AND S5 |
| S7 | 1 | S1 AND (LEUPROLIDE) |

?

S S1 AND (THYMUS (W) (ACTIVATION OR REACTIVATION))

| | | |
|----|---------|--|
| | 41571 | S1 |
| | 196864 | THYMUS |
| | 1725243 | ACTIVATION |
| | 44401 | REACTIVATION |
| | 26 | THYMUS(W) (ACTIVATION OR REACTIVATION) |
| S8 | 0 | S1 AND (THYMUS (W) (ACTIVATION OR REACTIVATION)) |

?

S (THYMUS (W) (ACTIVATION OR REACTIVATION))

| | | |
|----|---------|---|
| | 196864 | THYMUS |
| | 1725243 | ACTIVATION |
| | 44401 | REACTIVATION |
| S9 | 26 | (THYMUS (W) (ACTIVATION OR REACTIVATION)) |

?

RD

| | | |
|-----|----|-------------------|
| S10 | 14 | RD (unique items) |
|-----|----|-------------------|

?

S S10 AND LEUPROLIDE

| | | |
|-----|------|--------------------|
| | 14 | S10 |
| | 5753 | LEUPROLIDE |
| S11 | 0 | S10 AND LEUPROLIDE |

?

T S10/3,K/ALL

10/3,K/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

15219554 PMID: 15579436

Role of metalloelastase in a model of allergic lung responses induced by cockroach allergen.

Warner Roscoe L; Lukacs Nicholas W; Shapiro Steven D; Bhagarvathula Narasimharao; Nerusu Kamalakara C; Varani James; Johnson Kent J

Department of Pathology, The University of Michigan, 1301 Catherine Rd., Box 0602, Ann Arbor, MI 48109, USA.

American journal of pathology (United States) Dec 2004, 165 (6) p1921-30, ISSN 0002-9440--Print Journal Code: 0370502

Contract/Grant No.: R01-HL-48889; HL; NHLBI
Publishing Model Print
Document type: Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... of the chemotactic factors interleukin-5, macrophage inflammatory protein-1 alpha, monocyte chemoattractant protein-1, thymus activation regulated chemokine, and the proinflammatory cytokine tumor necrosis factor-alpha were significantly reduced in the...

10/3,K/2 (Item 2 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

14710665 PMID: 14691172

Chemokines in autoimmune lacrimal gland disease in MRL/MpJ mice.
Akpek Esen Karamursel; Jabs Douglas A; Gerard Herve C; Prendergast Robert A; Hudson Alan P; Lee Bella; Whittum-Hudson Judith A
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore Maryland, USA.
Investigative ophthalmology & visual science (United States) Jan 2004, 45 (1) p185-90, ISSN 0146-0404--Print Journal Code: 7703701
Contract/Grant No.: AI-44493; AI; NIAID; AR-48331; AR; NIAMS; EY05912; EY; NEI
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

... monocyte chemoattractant protein (MCP)-1 (also known as chemokine ligand [CCL]-2), MCP-5 (CCL12), thymus activation regulated chemokine (TARC; or CCL17), and macrophage-derived chemokine (MDC; or CCL22). Additional lacrimal glands...

10/3,K/3 (Item 3 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

13761693 PMID: 12023397

Diesel exposure favors Th2 cell recruitment by mononuclear cells and alveolar macrophages from allergic patients by differentially regulating macrophage-derived chemokine and IFN-gamma-induced protein-10 production.
Fahy Olivier; Senechal Stephanie; Pene Jerome; Scherpereel Arnaud; Lassalle Philippe; Tonnel Andre-Bernard; Yssel Hans; Wallaert Benoit; Tsicopoulos Anne
Institut National de la Sante et de la Recherche Medicale Unite 416, Institut Pasteur de Lille, Lille, France.
Journal of immunology (Baltimore, Md. - 1950) (United States) Jun 1 2002, 168 (11) p5912-9, ISSN 0022-1767--Print Journal Code: 2985117R
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM

Record type: MEDLINE; Completed

... to be preferentially recruited by the chemokines eotaxin (CCL11), macrophage-derived chemokine (MDC, CCL22), and thymus activation-regulated chemokine (CCL17) through their interaction with CCR3 and CCR4, respectively, whereas type 1 T...

10/3,K/4 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

13102665 PMID: 11159520

Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function.

Gear A R; Suttitanamongkol S; Viisoreanu D; Polanowska-Grabowska R K; Raha S; Camerini D

Department of Biochemistry and Molecular Genetics, University of Virginia Health Sciences Center, USA.

Blood (United States) Feb 15 2001, 97 (4) p937-45, ISSN 0006-4971--Print Journal Code: 7603509

Contract/Grant No.: AI 39943; AI; NIAID

Publishing Model Print

Document type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... can play important accessory roles. It is now reported that the macrophage-derived chemokine (MDC), thymus activation-regulated chemokine (TARC), and stromal cell-derived factor one (SDF-1) are highly effective activators...

10/3,K/5 (Item 5 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2007 Dialog. All rts. reserv.

12388099 PMID: 10229836

Pertussis toxin-sensitive signal controls the trafficking of thymocytes across the corticomedullary junction in the thymus.

Suzuki G; Sawa H; Kobayashi Y; Nakata Y; Nakagawa K i; Uzawa A; Sakiyama H; Kakinuma S; Iwabuchi K; Nagashima K

Divisions of Radiation, The Fifth Research Group, National Institute of Radiological Sciences, Chiba, Japan. gsuzuki@nirs.go.jp

Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) May 15 1999, 162 (10) p5981-5, ISSN 0022-1767--Print Journal Code: 2985117R

Publishing Model Print

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... CD8+ single-positive (SP) cells. Positively selected CD69+CD3intermediate cells gained CCR4, of which ligand, thymus activation-regulated chemokine, was expressed in the medulla. At the next developmental stage, CD69-CD3high cells...

10/3,K/6 (Item 1 from file: 159)
DIALOG(R)File 159:Cancerlit
(c) format only 2002 Dialog. All rts. reserv.

01219105 PMID: 80646571

[NONCONVENTIONAL METHODS: CELL THERAPY IN CANCER.]
AUSSENSEITERMETHODEN: ZELLTHERAPIE BEI KREBSERKRANKUNGEN.
Baenkler
Institut fur klinische Immunologie und Rheumatologie, Krankenhausstr. 12,
D-8520 Erlangen, W. Germany
MMW Munch Med Wochenschr 1980, 122 (1) p20-22, ISSN 0341-3098
Document Type: JOURNAL ARTICLE
Languages: GERMAN
Main Citation Owner: NOTNLM
Record type: Completed

... The cellular immunity cannot be appreciably activated in cancer patients by inoculation with animal fetal thymus . Activation of human lymphocytes against oncofetal antigens, especially carcinoembryonic antigen, of animal cells was observed, but...

10/3,K/7 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

0019429934 BIOSIS NO.: 200700089675

Mechanism of the salutary effects of flutamide on intestinal myeloperoxidase activity following trauma-hemorrhage: up-regulation of estrogen receptor-beta-dependent HO-1
AUTHOR: Yu Huang-Ping; Choudhry Mashkoor A; Shimizu Tomoharu; Hsieh Ya-Ching; Schwacha Martin G; Yang Shaolong; Chaudry Irshad H (Reprint)
AUTHOR ADDRESS: Univ Alabama, Ctr Surg Res, 1670 Univ Blvd,Volker Hall,Rm G094, Birmingham, AL 35294 USA**USA
AUTHOR E-MAIL ADDRESS: Irshad.Chaudry@ccc.uab.edu
JOURNAL: Journal of Leukocyte Biology 79 (2): p277-284 FEB 2006 2006
ISSN: 0741-5400
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ... thymus - activation -regulated chemokine {TARC

10/3,K/8 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

19177610 BIOSIS NO.: 200600523005

Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer
AUTHOR: Nakanishi Toru; Imaizumi Kazuyoshi; Hasegawa Yoshinori (Reprint); Kawabe Tsutomu; Hashimoto Naozumi; Okamoto Masakazu; Shimokata Kaoru
AUTHOR ADDRESS: Nagoya Univ, Grad Sch Med, Dept Resp Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan**Japan
AUTHOR E-MAIL ADDRESS: yhasega@med.nagoya-u.ac.jp
JOURNAL: Cancer Immunology Immunotherapy 55 (11): p1320-1329 NOV 2006 2006
ISSN: 0340-7004
DOCUMENT TYPE: Article

RECORD TYPE: Abstract
LANGUAGE: English

DESCRIPTORS:

...GENE NAME: human TARC gene (Hominidae) {human thymus - activation
-regulated chemokine gene...

10/3,K/9 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

19176117 BIOSIS NO.: 200600521512

Effects of nano particles on cytokine expression in murine lung in the
absence or presence of allergen

AUTHOR: Inoue Ken-ichiro; Takano Hirohisa (Reprint); Yanagisawa Rie;
Ichinose Takamichi; Sakurai Miho; Yoshikawa Toshikazu
AUTHOR ADDRESS: Natl Inst Environm Studies, Environm Hlth Sci Div, 16-2
Onogawa, Tsukuba, Ibaraki 3058506, Japan**Japan
AUTHOR E-MAIL ADDRESS: htakano@nies.go.jp
JOURNAL: Archives of Toxicology 80 (9): p614-619 SEP 2006 2006
ISSN: 0340-5761
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ... thymus activation -regulated chemokine

10/3,K/10 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17446978 BIOSIS NO.: 200300405697

Suppressive effect of combination treatment of leflunomide and methotrexate
on chemokine expression in patients with rheumatoid arthritis.

AUTHOR: Ho C Y; Wong C K; Li E K; Tam L S; Lam C W K (Reprint)
AUTHOR ADDRESS: Department of Chemical Pathology, Prince of Wales Hospital,
The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China**China
AUTHOR E-MAIL ADDRESS: waikeilam@cuhk.edu.hk
JOURNAL: Clinical and Experimental Immunology 133 (1): p132-138 July 2003
2003
MEDIUM: print
ISSN: 0009-9104 (ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ... thymus - activation regulated chemokine
{TARC}

10/3,K/11 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

10042144 BIOSIS NO.: 199039095533

THE ROLE OF DIACYLGLYCEROL KINASE ISOZYMES IN CELL FUNCTION

BOOK TITLE: NISHIZUKA, Y., M. ENDO AND C. TANAKA (ED.). ADVANCES IN SECOND MESSENGER AND PHOSPHOPROTEIN RESEARCH, VOL. 24. THE BIOLOGY AND MEDICINE OF SIGNAL TRANSDUCTION; 7TH INTERNATIONAL CONFERENCE ON CYCLIC NUCLEOTIDES, CALCIUM AND PROTEIN PHOSPHORYLATION, KOBE, JAPAN, OCTOBER 8-13, 1989. XXXIII+750P. RAVEN PRESS: NEW YORK, NEW YORK, USA. ILLUS
AUTHOR: KANO H (Reprint); YAMADA K; SAKANE F
AUTHOR ADDRESS: DEP BIOCHEM, SAPPORO MED COLL, SAPPORO 060, JPN**JAPAN
SERIES TITLE: Advances in Second Messenger and Phosphoprotein Research p584 1990
ISSN: 1040-7952 ISBN: 0-88167-670-5
DOCUMENT TYPE: Book; Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

DESCRIPTORS: ABSTRACT PIG THYMUS ACTIVATION SIGNAL TRANSDUCTION

10/3,K/12 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

07591262 BIOSIS NO.: 198579010161
THE BLOOD SYSTEM RESPONSE TO THE ADMINISTRATION OF THE BONE MARROW MEDIATOR STIMULATING ANTIBODY PRODUCTION
AUTHOR: GORIZONTOV P D; BELOUSOVA O I; ALFEROVA E M; MIKHAILOVA A A
JOURNAL: Gematologiya i Transfuziologiya 29 (4): p28-31 1984
ISSN: 0234-5730
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: RUSSIAN

...ABSTRACT: bone marrow. Later there was observed mobilization of lymphoid cells from the bone marrow and thymus , activation of granulocytopoiesis in the bone marrow and lymphocytopoiesis in the spleen.

10/3,K/13 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

12335222 EMBASE No: 2003440340
New horizons in the management of allergy
Ferguson B.J.
Dr. B.J. Ferguson, Eye and Ear Institute, 200 Lothrop Street, Pittsburgh, PA 15213 United States
AUTHOR EMAIL: bjferg@pitt.edu
Otolaryngologic Clinics of North America (OTOLARYNGOL. CLIN. NORTH AM.)
(United States) 2003, 36/5 (771-779)
CODEN: OCNAB ISSN: 0030-6665
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 26

DRUG TERMS (UNCONTROLLED): thymus activation regulated chemokine;
thymus activation regulated chemokine antibody--pharmacology--pd;
immunostimulatory sequence oligodeoxynucleotide--drug development--dv;
immunostimulatory sequence oligodeoxynucleotide--drug...

10/3,K/14 (Item 2 from file: 73)
 DIALOG(R)File 73:EMBASE
 (c) 2007 Elsevier B.V. All rts. reserv.

10958669 EMBASE No: 2001003584

Chemokines define distinct microenvironments in the developing thymus

Bleul C.C.; Boehm T.

T. Boehm, MPI fur Immunbiologie, Stuebeweg 51, D-79108 Freiburg Germany

AUTHOR EMAIL: boehm@immunbio.mpg.de

European Journal of Immunology (EUR. J. IMMUNOL.) (Germany) 2000,
 30/12 (3371-3379)

CODEN: EJIMA ISSN: 0014-2980

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 38

...DRUG TERMS (UNCONTROLLED): compound--ec; secondary lymphoid tissue
 chemokine--endogenous compound--ec; macrophage derived chemokine
 --endogenous compound--ec; thymus activation regulated chemokine
 --endogenous compound--ec
 ?

| Set | Items | Description |
|-----|-------|---|
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| S3 | 10 | S1 AND S2 |
| S4 | 6 | RD (unique items) |
| S5 | 760 | (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING) |
| S6 | 0 | S1 AND S5 |
| S7 | 1 | S1 AND (LEUPROLIDE) |
| S8 | 0 | S1 AND (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S9 | 26 | (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S10 | 14 | RD (unique items) |
| S11 | 0 | S10 AND LEUPROLIDE |

?

S S1 AND (IL-7)
 41571 S1
 44 IL-7
 S12 0 S1 AND (IL-7)
 ?

| Set | Items | Description |
|-----|-------|---|
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| S3 | 10 | S1 AND S2 |
| S4 | 6 | RD (unique items) |
| S5 | 760 | (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING) |
| S6 | 0 | S1 AND S5 |
| S7 | 1 | S1 AND (LEUPROLIDE) |
| S8 | 0 | S1 AND (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S9 | 26 | (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S10 | 14 | RD (unique items) |
| S11 | 0 | S10 AND LEUPROLIDE |

S12 0 S1 AND (IL-7)

?

S (HIGHLY (W) ACTIVE (W) RETROVIRAL (W) THERAPY)

1266787 HIGHLY

1500617 ACTIVE

56467 RETROVIRAL

6909252 THERAPY

S13 136 (HIGHLY (W) ACTIVE (W) RETROVIRAL (W) THERAPY)

?

| Set | Items | Description |
|-----|-------|---|
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| S3 | 10 | S1 AND S2 |
| S4 | 6 | RD (unique items) |
| S5 | 760 | (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING) |
| S6 | 0 | S1 AND S5 |
| S7 | 1 | S1 AND (LEUPROLIDE) |
| S8 | 0 | S1 AND (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S9 | 26 | (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S10 | 14 | RD (unique items) |
| S11 | 0 | S10 AND LEUPROLIDE |
| S12 | 0 | S1 AND (IL-7) |
| S13 | 136 | (HIGHLY (W) ACTIVE (W) RETROVIRAL (W) THERAPY) |

?

S S1 AND S13

41571 S1

136 S13

S14 0 S1 AND S13

?

| Set | Items | Description |
|-----|-------|---|
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| S3 | 10 | S1 AND S2 |
| S4 | 6 | RD (unique items) |
| S5 | 760 | (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING) |
| S6 | 0 | S1 AND S5 |
| S7 | 1 | S1 AND (LEUPROLIDE) |
| S8 | 0 | S1 AND (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S9 | 26 | (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S10 | 14 | RD (unique items) |
| S11 | 0 | S10 AND LEUPROLIDE |
| S12 | 0 | S1 AND (IL-7) |
| S13 | 136 | (HIGHLY (W) ACTIVE (W) RETROVIRAL (W) THERAPY) |
| S14 | 0 | S1 AND S13 |

?

S S13 AND S2

136 S13

154 S2

S15 0 S13 AND S2

?

| Set | Items | Description |
|-----|-------|---|
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| S3 | 10 | S1 AND S2 |
| S4 | 6 | RD (unique items) |
| S5 | 760 | (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING) |
| S6 | 0 | S1 AND S5 |
| S7 | 1 | S1 AND (LEUPROLIDE) |
| S8 | 0 | S1 AND (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S9 | 26 | (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S10 | 14 | RD (unique items) |
| S11 | 0 | S10 AND LEUPROLIDE |
| S12 | 0 | S1 AND (IL-7) |
| S13 | 136 | (HIGHLY (W) ACTIVE (W) RETROVIRAL (W) THERAPY) |
| S14 | 0 | S1 AND S13 |
| S15 | 0 | S13 AND S2 |

?

S S12 AND (HIV)

| | | |
|-----|--------|---------------|
| | 0 | S12 |
| | 459839 | HIV |
| S16 | 0 | S12 AND (HIV) |

?

| Set | Items | Description |
|-----|-------|---|
| S1 | 41571 | (HSC OR (STEM (W) CELLS) OR (BONE (W) MARROW)) (S) (DNA OR VECTOR OR TRANSFECTED OR (GENETICALLY (W) MODIFIED)) |
| S2 | 154 | (RIBOZYME) (S) (TAT AND HIV) |
| S3 | 10 | S1 AND S2 |
| S4 | 6 | RD (unique items) |
| S5 | 760 | (SEX (W) STEROID) (S) (INHIBITION OR DISRUPTION OR BLOCKAGE OR DISRUPTING) |
| S6 | 0 | S1 AND S5 |
| S7 | 1 | S1 AND (LEUPROLIDE) |
| S8 | 0 | S1 AND (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S9 | 26 | (THYMUS (W) (ACTIVATION OR REACTIVATION)) |
| S10 | 14 | RD (unique items) |
| S11 | 0 | S10 AND LEUPROLIDE |
| S12 | 0 | S1 AND (IL-7) |
| S13 | 136 | (HIGHLY (W) ACTIVE (W) RETROVIRAL (W) THERAPY) |
| S14 | 0 | S1 AND S13 |
| S15 | 0 | S13 AND S2 |
| S16 | 0 | S12 AND (HIV) |

?

COST

```

07nov07 17:21:45 User259876 Session D1049.2
$5.79 1.702 DialUnits File155
$1.98 9 Type(s) in Format 3
$1.98 9 Types
$7.77 Estimated cost File155
$1.71 0.543 DialUnits File159
$0.26 1 Type(s) in Format 3
$0.26 1 Types

```

\$1.97 Estimated cost File159
\$12.05 2.009 DialUnits File5
\$16.10 7 Type(s) in Format 3
\$16.10 7 Types
\$28.15 Estimated cost File5
\$20.18 1.696 DialUnits File73
\$13.20 4 Type(s) in Format 3
\$13.20 4 Types
\$33.38 Estimated cost File73
OneSearch, 4 files, 5.949 DialUnits FileOS
\$2.93 INTERNET
\$74.20 Estimated cost this search
\$75.24 Estimated total session cost 6.228 DialUnits

?

Return to logon page!

Refine Search

Search Results -

| Term | Documents |
|---|-----------|
| (11 AND 14).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD. | 2 |
| (L14 AND L11).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD. | 2 |

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

Search History

DATE: Wednesday, November 07, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

| Set Name | Query | Hit Count | Set Name |
|---|---|--------------|-------------|
| side by side | | | |
| result set | | | |
| DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; | | | |
| OP=AND | | | |
| <u>L16</u> | L14 and L11 | 2 | <u>L16</u> |
| <u>L15</u> | L14 and (Leuprolide) | 25 | <u>L15</u> |
| <u>L14</u> | L13 same (recipient or donor) | 705 | <u>L14</u> |
| <u>L13</u> | L3 same (transplant or transplantation or implantation) | 4667 | <u>L13</u> |
| <u>L12</u> | L11 and L9 | 8 | <u>L12</u> |
| <u>L11</u> | (sex adj steroid) same (inhibition or disruption or blockage or disrupting) | 258 | <u>L11</u> |
| <u>L10</u> | L9 and (Leuprolide) | 8 | <u>L10</u> |
| <u>L9</u> | L7 and L3 | 134 | <u>L9</u> |
| <u>L8</u> | L7 and L6 | 8 | <u>L8</u> |
| <u>L7</u> | (ribozyme) same (tat and HIV) | 243 | <u>L7</u> |
| <u>L6</u> | L5 and (HIV) | 1305 | <u>L6</u> |

| | | | |
|-----------|---|-------|-----------|
| <u>L5</u> | L4 and (Leuprolide) | 1550 | <u>L5</u> |
| <u>L4</u> | L3 and (transplantation or implantation) | 12738 | <u>L4</u> |
| <u>L3</u> | (HSC or (stem adj cell) or (bone adj marrow)) same (DNA or vector or transfected or (genetically adj modified)) | 26280 | <u>L3</u> |
| <u>L2</u> | L1 and (HIV and HSC) | 9 | <u>L2</u> |
| <u>L1</u> | Boyd-Richard-L\$.in. | 14 | <u>L1</u> |

END OF SEARCH HISTORY